Structural insights into nucleocapsid protein variability: Implications for PJ34 efficacy against SARS-CoV-2

Area of Science:

• Virology
• Structural Biology
• Drug Discovery

Background:

• Human coronaviruses (HCoVs) range from common cold viruses to severe pathogens like SARS-CoV and SARS-CoV-2.
• The conserved nucleocapsid (N) protein is crucial for viral RNA binding and replication.

Purpose of the Study:

• To investigate the efficacy of compound PJ34, a known inhibitor of HCoV-OC43 N protein nucleic acid binding, against SARS-CoV-2.
• To understand the structural basis for differential drug response between HCoV-OC43 and SARS-CoV-2.

Main Methods:

• Previous studies on HCoV-OC43 N protein and compound PJ34.
• Testing of PJ34 efficacy against SARS-CoV-2 replication.
• Structural analysis of the SARS-CoV-2 N protein N-terminal domain (NTD).

Main Results:

• Compound PJ34 failed to inhibit SARS-CoV-2 replication.
• Structural differences, specifically a Tyr to Ala substitution at position 50 in SARS-CoV-2 N protein NTD (vs. Tyr63 in OC43), were identified.
• This substitution likely hinders PJ34 binding and explains its lack of efficacy.

Conclusions:

• The N protein remains a critical therapeutic target for broad-spectrum coronavirus drugs.
• Structure-based drug design is essential for developing effective inhibitors, accounting for specific viral variations.
• Targeting conserved regions or developing drugs specific to SARS-CoV-2 N protein variations is necessary.